Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence

• Main Authors: Pasquale Sansone (Author), Luca Gregorio Giaccari (Author), Francesco Coppolino (Author), Caterina Aurilio (Author), Alfonso Barbarisi (Author), Maria Beatrice Passavanti (Author), Vincenzo Pota (Author), Maria Caterina Pace (Author)
• Format: Book
• Published: MDPI AG, 2022-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

(1) Background: healthcare-associated infections are one of the most frequent adverse events in healthcare delivery worldwide. Several antibiotic resistance mechanisms have been developed, including those to carbapenemase. Cefiderocol (CFD) is a novel siderophore cephalosporin designed to treat carbapenem-resistant bacteria. (2) Methods: we performed a systematic review of all cases reported in the literature to outline the existing evidence. We evaluated real-world evidence studies of CFD in the treatment of carbapenem-resistant (CR) bacteria. (3) Results: a total of 19 publications treating cases of infection by CR bacteria were included. The three most frequent CR pathogens were <i>Acinetobacter baumannii</i>, <i>Pseudomonas aeruginosa</i>, and <i>Klebsiella pneumoniae</i>. A regimen of 2 g every 8 h was most frequently adopted for CFD with a mean treatment duration of 25.6 days. CFD was generally well tolerated, with fewer side effects. The success rate of CFD therapy was satisfactory and almost 70% of patients showed clinical recovery; of these, nearly half showed negative blood cultures and infection-free status. (4) Conclusions: This review indicates that CFD is active against important GN organisms including <i>Enterobacteriaceae, P. aeruginosa,</i> and <i>A. baumannii</i>. CFD seems to have a safe profile.

Item Description

10.3390/antibiotics11070904
2079-6382